Catechols in post‐mortem brain of patients with Parkinson disease
Identifieur interne : 000374 ( Main/Exploration ); précédent : 000373; suivant : 000375Catechols in post‐mortem brain of patients with Parkinson disease
Auteurs : D. S. Goldstein [États-Unis] ; P. Sullivan [États-Unis] ; C. Holmes [États-Unis] ; I. J. Kopin [États-Unis] ; M. J. Basile [États-Unis] ; D. C. Mash [États-Unis]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2011-05.
English descriptors
- KwdEn :
Abstract
Background: Dihydroxyphenylacetaldehyde (DOPAL), a cytotoxic metabolite of dopamine, is the focus of the ‘catecholaldehyde hypothesis’ about the pathogenesis of Parkinson disease. This study explored whether DOPAL is detectable in human striatum – especially in the putamen (Pu), the main site of dopamine depletion in Parkinson disease – and is related to other neurochemical indices of catecholamine stores and metabolism in Parkinson disease. Methods: Putamen, caudate (Cd), and frontal cortex (Ctx) catechols were measured in tissue from patients with pathologically proven end‐stage Parkinson disease (N = 15) and control subjects (N = 14) of similar age with similar post‐mortem intervals. Results: Putamen DOPAL (3% of dopamine in controls) correlated with dopamine and dihydroxyphenylacetic acid both across all subjects and within the Parkinson disease and control groups. Pu dopamine was decreased by 93% and dihydroxyphenylacetic acid 95% in Parkinson disease vs. controls, with smaller decreases of DOPAL (83%) and norepinephrine (73%) in Pu and of dopamine (74%) and dihydroxyphenylacetic acid (82%) in Cd. In Parkinson disease, Pu DOPAL:dihydroxyphenylacetic acid averaged 3.4 times and DOPAL:dopamine 4.4 times control (P = 0.03 each). The main catecholamine in Ctx was norepinephrine, which was decreased by 51% in Parkinson disease patients. Conclusions: Correlated decreases of DOPAL, dopamine, and dihydroxyphenylacetic acid in Parkinson disease reflect severe loss of Pu dopamine stores, which seems more extensive than loss of Pu norepinephrine or Cd dopamine stores. Increased Pu DOPAL:dihydroxyphenylacetic acid ratios in Parkinson disease suggest decreased detoxification of DOPAL by aldehyde dehydrogenase. Elevated levels of cytosolic DOPAL might contribute to loss of dopaminergic neurons in Parkinson disease.
Url:
DOI: 10.1111/j.1468-1331.2010.03246.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Catechols in post‐mortem brain of patients with Parkinson disease</title><author><name sortKey="Goldstein, D S" sort="Goldstein, D S" uniqKey="Goldstein D" first="D. S." last="Goldstein">D. S. Goldstein</name></author><author><name sortKey="Sullivan, P" sort="Sullivan, P" uniqKey="Sullivan P" first="P." last="Sullivan">P. Sullivan</name></author><author><name sortKey="Holmes, C" sort="Holmes, C" uniqKey="Holmes C" first="C." last="Holmes">C. Holmes</name></author><author><name sortKey="Kopin, I J" sort="Kopin, I J" uniqKey="Kopin I" first="I. J." last="Kopin">I. J. Kopin</name></author><author><name sortKey="Basile, M J" sort="Basile, M J" uniqKey="Basile M" first="M. J." last="Basile">M. J. Basile</name></author><author><name sortKey="Mash, D C" sort="Mash, D C" uniqKey="Mash D" first="D. C." last="Mash">D. C. Mash</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A8053DC4D0F138A958805F51B310A5D9348C2811</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1468-1331.2010.03246.x</idno><idno type="url">https://api.istex.fr/document/A8053DC4D0F138A958805F51B310A5D9348C2811/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000001</idno><idno type="wicri:Area/Main/Curation">000001</idno><idno type="wicri:Area/Main/Exploration">000374</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Catechols in post‐mortem brain of patients with Parkinson disease</title><author><name sortKey="Goldstein, D S" sort="Goldstein, D S" uniqKey="Goldstein D" first="D. S." last="Goldstein">D. S. Goldstein</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Sullivan, P" sort="Sullivan, P" uniqKey="Sullivan P" first="P." last="Sullivan">P. Sullivan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Holmes, C" sort="Holmes, C" uniqKey="Holmes C" first="C." last="Holmes">C. Holmes</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Kopin, I J" sort="Kopin, I J" uniqKey="Kopin I" first="I. J." last="Kopin">I. J. Kopin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Basile, M J" sort="Basile, M J" uniqKey="Basile M" first="M. J." last="Basile">M. J. Basile</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Mash, D C" sort="Mash, D C" uniqKey="Mash D" first="D. C." last="Mash">D. C. Mash</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-05">2011-05</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="703">703</biblScope><biblScope unit="page" to="710">710</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">A8053DC4D0F138A958805F51B310A5D9348C2811</idno><idno type="DOI">10.1111/j.1468-1331.2010.03246.x</idno><idno type="ArticleID">ENE3246</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term><term>aldehyde dehydrogenase</term><term>dihydroxyphenylacetaldehyde</term><term>dihydroxyphenylglycol</term><term>dopamine</term><term>norepinephrine</term><term>putamen</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Dihydroxyphenylacetaldehyde (DOPAL), a cytotoxic metabolite of dopamine, is the focus of the ‘catecholaldehyde hypothesis’ about the pathogenesis of Parkinson disease. This study explored whether DOPAL is detectable in human striatum – especially in the putamen (Pu), the main site of dopamine depletion in Parkinson disease – and is related to other neurochemical indices of catecholamine stores and metabolism in Parkinson disease. Methods: Putamen, caudate (Cd), and frontal cortex (Ctx) catechols were measured in tissue from patients with pathologically proven end‐stage Parkinson disease (N = 15) and control subjects (N = 14) of similar age with similar post‐mortem intervals. Results: Putamen DOPAL (3% of dopamine in controls) correlated with dopamine and dihydroxyphenylacetic acid both across all subjects and within the Parkinson disease and control groups. Pu dopamine was decreased by 93% and dihydroxyphenylacetic acid 95% in Parkinson disease vs. controls, with smaller decreases of DOPAL (83%) and norepinephrine (73%) in Pu and of dopamine (74%) and dihydroxyphenylacetic acid (82%) in Cd. In Parkinson disease, Pu DOPAL:dihydroxyphenylacetic acid averaged 3.4 times and DOPAL:dopamine 4.4 times control (P = 0.03 each). The main catecholamine in Ctx was norepinephrine, which was decreased by 51% in Parkinson disease patients. Conclusions: Correlated decreases of DOPAL, dopamine, and dihydroxyphenylacetic acid in Parkinson disease reflect severe loss of Pu dopamine stores, which seems more extensive than loss of Pu norepinephrine or Cd dopamine stores. Increased Pu DOPAL:dihydroxyphenylacetic acid ratios in Parkinson disease suggest decreased detoxification of DOPAL by aldehyde dehydrogenase. Elevated levels of cytosolic DOPAL might contribute to loss of dopaminergic neurons in Parkinson disease.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Goldstein, D S" sort="Goldstein, D S" uniqKey="Goldstein D" first="D. S." last="Goldstein">D. S. Goldstein</name></region><name sortKey="Basile, M J" sort="Basile, M J" uniqKey="Basile M" first="M. J." last="Basile">M. J. Basile</name><name sortKey="Holmes, C" sort="Holmes, C" uniqKey="Holmes C" first="C." last="Holmes">C. Holmes</name><name sortKey="Kopin, I J" sort="Kopin, I J" uniqKey="Kopin I" first="I. J." last="Kopin">I. J. Kopin</name><name sortKey="Mash, D C" sort="Mash, D C" uniqKey="Mash D" first="D. C." last="Mash">D. C. Mash</name><name sortKey="Sullivan, P" sort="Sullivan, P" uniqKey="Sullivan P" first="P." last="Sullivan">P. Sullivan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000374 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000374 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A8053DC4D0F138A958805F51B310A5D9348C2811
|texte= Catechols in post‐mortem brain of patients with Parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |